Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra and Restylane Lyft or Contour effectively improved the facial aesthetic appearance of patients experiencing medication-driven weight loss with associated facial volume loss 1 A six-month extension study is ongoing to capture the combined and sustained effects of these treatments over time Galderma is well-positioned to support patients specific needs in this area, given its unique expertise in dermatology, including aesthetics, and its individualized treatment approach developed in close collaboration with healthcare professionals Zug, Switzerland January 14, 2025 Galderma announces positive first results from a trial designed to explore the benefits of Restylane Lyft or Contour in combination with Sculptra in patients with medication-driven weight loss with associated facial volume loss
The primary concern with hepatic impairment is a potential change in exposure to a drug that is extensively cleared by hepatic metabolism or biliary excretion via the liver, that could impact on the pharmacodynamic action or lead to adverse effects [19]
Also advancing an amylin candidate is AstraZeneca, which is positioning its AZD6234 as a potential alternative or complement to GLP-1 therapies
American Diabetes Association Management of hyperglycemia in Type 2 Diabetes
Sofwave is an FDA-cleared, non-invasive ultrasound technology that improves facial lines and wrinkles and lifts: the eyebrows lax skin of the neck lax submental (under-chin) tissue It does not replace lost fat, but can help improve the appearance of wrinkles in specific areas
Relevant to appetite-associated signaling, insulinotropic pathway biology, gastric-emptying models, adipose-associated signaling, and energy-balance research
